9 million Magpies! More than 20 billion oral anti-sugar drug market blasted

　　Pharmaceutical Network November 30, November 29, Yabao Pharmaceuticals issued a notice that the company received the State Drug Administration approved the issuance of benzoic acid agretin tablets "drug registration approval." Data show that benzoic acid agretin tablets were first developed by Takeda Pharmaceutical Industry Co., Ltd of Japan, listed in Japan in 2010, in 2013 in China approved imported drugs listed, the commodity name "Nihina." Table 1:
Approval Sped main content (Source: Company Announcement) Figure 1: Annual sales trend of end chemical drugs oral diabetes in China's public medical institutions (unit: 10,000 yuan) (source: Minet China public medical institutions terminal competition pattern) Figure 2: Annual sales of end chemical drugs agretin in China's public medical institutions Trends (units: 10,000 yuan) (source: Minet.com China's public medical institutions terminal competition pattern) meters net data show that in 2018 in China's urban public , county-level public hospitals, urban community centers and township health hospitals (referred to as China's public medical institutions) terminal chemical drug oral diabetes market size has reached 25.6 billion yuan it is reported that benzoic acid agregintableta is mainly used to treat type 2 diabetes, first developed by Japan's Takeda Pharmaceutical Industry Co., Ltd and listed in Japan in 2010, the global sales of the product in 2017 showed global sales of 53.7 billion yen (about $500 million) in 2013, the original research products in China was approved for import listing, the commodity name "Nishina", in 2018 in China's public medical institutions terminal sales reached 62.85 million yuan, a growth rate of 187.68 percent, the product for the 2019 version of the National Health Insurance Catalog B products, products into the domestic will usher in market volume Yabao Pharmaceuticals said in a notice that the company's first submission of benzoic acid agretin tablet registration application processing time is February 22, 2017, there is no other company other than the company to obtain benzoic acid agretin tablets registration approval Up to now, the company has invested in research and development projects of the product about 8.89 million yuan -meter net MED China Drug Review Database 2.0 data show that as of November 29, 2019, benzoic acid agretin tablets in the trial of the imitation listing application
as well as Shenzhen Seaside Pharmaceuticals, Stone Pharmaceuticals, Hunan Qianjin Xiangjiang Pharmaceuticals, National Pharmaceutical Group Guorui Pharmaceuticals, Guangdong Dongsun Pharmaceuticals, Jiangsu Notai O's Sino-Biopharmaceuticals, Jiangsu Zhongtian Pharmaceuticals, Jiangsu Deyuan Pharmaceuticals, the registration of 4 sources: Internet database, announcement of listed companies